Orphazyme AS (CHIX:ORPHAC) EBIT : kr-591.94 Mil (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS EBIT?

Orphazyme AS's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2022 was kr-27.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2022 was kr-591.94 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Orphazyme AS's annualized ROC % for the quarter that ended in Jun. 2022 was -222.44%. Orphazyme AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -1,297.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Orphazyme AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was 4,011.26%.

Orphazyme AS EBIT Historical Data

The historical data trend for Orphazyme AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS EBIT Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-131.02

-232.28

-338.19

-621.05

-622.02

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EBIT	Get a 7-Day Free Trial									-245.43	-375.62	-57.32	-564.70	-27.24

Competitive Comparison of Orphazyme AS's EBIT

For the Biotechnology subindustry, Orphazyme AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's EV-to-EBIT falls into.

Orphazyme AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-591.94 Mil.

Orphazyme AS (CHIX:ORPHAc) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Orphazyme AS's annualized ROC % for the quarter that ended in Jun. 2022 is calculated as:

	ROC % (Q: Jun. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2021 )	+	Invested Capital (Q: Jun. 2022 ))	/ count )
=	-109.184 * ( 1 - 10.25% )	/	( (55.747	+	32.361)	/ 2 )
=	-97.99264	/	44.054
=	-222.44 %

where

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	173.229	-	87.63	-	( 102.255	-	max(0, 129.092	-	158.944	+	102.255	))
=	55.747

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	93.589	-	11.696	-	( 49.532	-	max(0, 15.384	-	88.089	+	49.532	))
=	32.361

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Orphazyme AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2021		Q: Jun. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-108.956	/	( ( (8.419 + max(-53.391, 0))	+	(0 + max(8.381, 0)) )	/	2 )
=	-108.956	/	( ( 8.419	+	8.381 )	/	2 )
=	-108.956	/	8.4
=	-1,297.10 %

where Working Capital is:

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(29.268	+	0	+	12.872)	-	(87.63	+	0	+	7.901)
=	-53.391

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(23.765	+	0	+	0)	-	(11.696	+	0	+	3.688)
=	8.381

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Orphazyme AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2022 )
	=	-591.942	/	-14.757
	=	4,011.26 %

Orphazyme AS EBIT Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines